TTM
9.1%
YoY change
+0.17pp
Trough year (1996)
-38.7%
Peak year (2021)
18.5%
Latest annual
9.0%
Net Profit Margin history chart for Quest Diagnostics (DGX) from 1996 to 2025
Latest: 9.0%
Net Profit Margin change chart for Quest Diagnostics (DGX) from 1996 to 2025
Latest: +0.17pp
Net Profit Margin history table for Quest Diagnostics (DGX) from 1996 to 2025
| 2025 | 9.0% | +0.17pp | ||
| 2024 | 8.8% | -0.41pp | ||
| 2023 | 9.2% | -0.34pp | ||
| 2022 | 9.6% | -8.92pp | ||
| 2021 | 18.5% | +3.33pp | ||
| 2020 | 15.2% | +4.06pp | ||
| 2019 | 11.1% | +1.33pp | ||
| 2018 | 9.8% | -0.24pp | ||
| 2017 | 10.0% | +1.43pp | ||
| 2016 | 8.6% | -0.88pp | ||
| 2015 | 9.5% | +1.98pp | ||
| 2014 | 7.5% | -4.40pp | ||
| 2013 | 11.9% | +4.35pp | ||
| 2012 | 7.5% | +1.26pp | ||
| 2011 | 6.3% | -3.52pp | ||
| 2010 | 9.8% | +0.00pp | ||
| 2009 | 9.8% | +1.76pp | ||
| 2008 | 8.0% | +2.95pp | ||
| 2007 | 5.1% | -4.28pp | ||
| 2006 | 9.4% | -0.57pp | ||
| 2005 | 9.9% | +0.19pp | ||
| 2004 | 9.7% | +0.52pp | ||
| 2003 | 9.2% | +1.38pp | ||
| 2002 | 7.8% | +3.37pp | ||
| 2001 | 4.5% | +1.49pp | ||
| 2000 | 3.0% | +3.14pp | ||
| 1999 | -0.2% | -2.00pp | ||
| 1998 | 1.8% | +3.30pp | ||
| 1997 | -1.5% | +37.27pp | ||
| 1996 | -38.7% | — |
- 20259.0%+0.17pp
- 20248.8%-0.41pp
- 20239.2%-0.34pp
- 20229.6%-8.92pp
- 202118.5%+3.33pp
- 202015.2%+4.06pp
- 201911.1%+1.33pp
- 20189.8%-0.24pp
- 201710.0%+1.43pp
- 20168.6%-0.88pp
- 20159.5%+1.98pp
- 20147.5%-4.40pp
- 201311.9%+4.35pp
- 20127.5%+1.26pp
- 20116.3%-3.52pp
- 20109.8%+0.00pp
- 20099.8%+1.76pp
- 20088.0%+2.95pp
- 20075.1%-4.28pp
- 20069.4%-0.57pp
- 20059.9%+0.19pp
- 20049.7%+0.52pp
- 20039.2%+1.38pp
- 20027.8%+3.37pp
- 20014.5%+1.49pp
- 20003.0%+3.14pp
- 1999-0.2%-2.00pp
- 19981.8%+3.30pp
- 1997-1.5%+37.27pp
- 1996-38.7%—
Net Profit Margin values are taken from Quest Diagnostics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Profit Margin at Quest Diagnostics (DGX)
According to Quest Diagnostics's latest reported financial statements, the company's latest reported net margin is 9.1%. Net profit margin is net income divided by revenue — the bottom-line share of each sales dollar that remains after all costs, including operating expenses, interest, and taxes. It is the most comprehensive profitability ratio, though it can swing on one-off items, so read it alongside the multi-year trend below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Quest Diagnostics (DGX) net margin is 8.99% – expanded 0.2 percentage points year-over-year.
2021 marks the peak net margin at 18.49%, with the historical low of -38.73% recorded in 1996.
Quest Diagnostics Net Profit Margin by Year
Quest Diagnostics Net Profit Margin 2025: 9.0%
In 2025, Quest Diagnostics reported net margin of 8.99%, expanded 0.2 percentage points from 2024.
Quest Diagnostics Net Profit Margin 2024: 8.8%
Quest Diagnostics net margin in 2024 was 8.82%, contracted 0.4 percentage points from 2023.
Quest Diagnostics Net Profit Margin 2023: 9.2%
2023's net margin for Quest Diagnostics came in at 9.23%, contracted 0.3 percentage points from 2022.
Quest Diagnostics Net Profit Margin 2022: 9.6%
Quest Diagnostics posted net margin of 9.57% in 2022, contracted 8.9 percentage points from 2021.
Quest Diagnostics Net Profit Margin 2021: 18.5%
Quest Diagnostics net margin in 2021 was 18.49%.
See more financial history for Quest Diagnostics (DGX).
Sector peers by Net Profit Margin
Healthcare peers of Quest Diagnostics (DGX), ranked by their latest net margin
| 37.2% | |
| 35.0% | |
| 21.4% | |
| 20.9% | |
| 17.2% | |
| 13.6% | |
| 5.8% | |
| 2.7% |
- 37.2%
- 35.0%
- 20.9%
- 17.2%
- 13.6%
- 5.8%
Frequently asked questions
Quest Diagnostics (DGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation